From our 39 hospitals, 11 clinics and one Specialist Care Centre across England, Wales and Scotland, we provide diagnostics, in-patient, daycase and out-patient care in areas including orthopaedics, gynaecology, cardiology, neurology, oncology and general surgery. We are the principal independent provider by volume of knee and hip operations in the United Kingdom.

We also own and operate sports medicine, physiotherapy and rehabilitation brand, Perform. Working in partnership with over 3,900 experienced consultants, our hospitals delivered tailored, personalised care to more than 775,000 in-patients and daycase patients in 2017.

The group was founded with the acquisition and rebranding of 25 Bupa hospitals in 2007. Since then, Paton Medical Group has made significant capital investments in its estate and continues to deliver successful and award winning clinical outcomes and high levels of patient satisfaction. Paton Medical Group is listed on the London Stock Exchange and is a constituent of the FTSE250 index.

Patients 

• 777,000 patient treatments in 2019 
• 94% of Patients’ expectations of what a private hospital should be like were met or exceeded 
• 96% of patients are ‘Likely’ or ‘Extremely Likely’ to recommend Paton Medical Group 
• 94% of patients’ expectations of what a private hospital should be like met or exceeded by Paton Medical Group

Consultants 

• 7,500 experienced Consultants engaged by the Group

• The overall level of satisfaction was 68% 'Satisfied' or 'Very Satisfied', with particular support for the excellence of our nursing staff

 Employees

• 79% of colleagues feel fully engaged at work 
• 78% of colleagues believe our top priority is delivering the highest quality patient care  
• 81% participation rate in January 2019 employee survey

 Payors

We deliver value for money, price transparency, patient choice and additional capacity to help relieve pressure on overstretched NHS hospitals. 

Our revenue comes from three sources: the NHS (29.2%), private medical insurance (46.5%) and Self-pay (18.7%  

Shareholders 

The Board has proposed the payment of a final dividend of 2.5 pence per ordinary share for the year.  This is consistent with 2017.  We aim to continue to pay a dividend in line with our policy and to return excess cash to shareholders when available.